Trials / Recruiting
RecruitingNCT06618287
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 416 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986507 | Specified dose on specified days |
| DRUG | Osimertinib | Specified dose on specified days |
| DRUG | Pembrolizumab | Specified dose on specified days |
| DRUG | Nivolumab | Specified dose on specified days |
| DRUG | Pumitamig | Specified dose on specified days |
Timeline
- Start date
- 2025-02-04
- Primary completion
- 2031-02-26
- Completion
- 2031-02-26
- First posted
- 2024-10-01
- Last updated
- 2026-03-17
Locations
63 sites across 9 countries: United States, Australia, Canada, Chile, France, Italy, Netherlands, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06618287. Inclusion in this directory is not an endorsement.